How Ibogaine Went From a Schedule I Ghost Story to a Trump Executive Order in One Spring

Marcus Capone was a Navy SEAL for thirteen years. He came home with the kind of traumatic brain injury and post-traumatic stress that the VA’s standard toolkit — SSRIs, talk therapy, a rotating cast of diagnoses — never resolved. What did, according to Capone and the veterans’ nonprofit he founded, Veterans Exploring Treatment Solutions, was ibogaine: a psychoactive alkaloid derived from the root bark of a West African shrub, administered at a clinic outside the United States because no version of it is legal to prescribe here. VETS has since helped more than a thousand veterans travel abroad for the same treatment. That number — a thousand Americans leaving the country to access a drug their own government classifies as having no accepted medical use — is the pressure that’s been building under this story for years. This spring, it broke through.

A federal government that has treated ibogaine as Schedule I contraband since 1970 just cleared its first-ever human trial of the drug in fifty-six years — not because the safety science caught up, but because a coalition of veterans, a health secretary, and a governor’s race in Texas made the politics move faster than the evidence.

The executive order came before the trial data did

On April 18, President Trump signed an executive order directing HHS and the FDA to accelerate research, approval, and access to psychedelic therapies, with ibogaine named specifically and veterans named as the priority population. HHS Secretary Robert F. Kennedy Jr. has been the public face of the push, calling the moment “historic” and framing psychedelic medicine as central to his “Make America Healthy Again” platform — a framing that has done something unusual in American drug policy: it has made a Schedule I psychedelic a cause conservatives champion instead of one they campaign against. Rick Perry, the former Texas governor and Trump cabinet member, has joined VETS in lobbying for it. Texas backed the shift with money, not just rhetoric: the state legislature approved $50 million to fund ibogaine research — the largest public grant of its kind anywhere.

Six days after the executive order, the FDA delivered the regulatory piece: on April 24, the agency cleared an Investigational New Drug application from DemeRx to begin a Phase I U.S. trial of DMX-1001, an oral formulation of noribogaine — ibogaine’s active metabolite — as a treatment for alcohol use disorder, a condition that affects roughly 29 million Americans and kills more than 140,000 of them a year. It is the first time the U.S. government has allowed a clinical study of any ibogaine-derived compound on American soil. The same week, the FDA handed out national priority review vouchers to companies studying psilocybin for depression and methylone — an MDMA relative — for PTSD, compressing standard review timelines from ten months to six.

The part the executive order can’t fast-track

Here’s the caveat a careful reader — or a clinician taking a referral call about it — needs before any of this reads as “ibogaine is basically approved now”: it isn’t, and the safety profile is the reason regulators moved this slowly for half a century in the first place. Ibogaine has been linked to more than 30 deaths in the medical literature, primarily from cardiac arrhythmia — the compound prolongs the heart’s QT interval, and unsupervised or underground administration (which is how most of those thousand veterans received it, at clinics outside FDA oversight) carries real cardiac risk that a Phase I trial is specifically designed to characterize before anyone scales this up. Some psychiatric researchers have said as much publicly: the hope has outrun the science, and a White House press event is not a substitute for the years of dose-ranging and cardiac-monitoring data a drug this physiologically active actually requires. A Phase I trial answers safety and dosing questions in a small group. It does not answer whether DMX-1001 works for alcohol use disorder at scale, and it is years away from a prescription pad regardless of how fast the political tailwind is blowing.

A Phase I trial answers safety and dosing questions in a small group.

That gate matters for a second reason beyond safety: even a full FDA approval would not instantly make ibogaine legal to prescribe in every state, reimbursable by every payer, or administered by every provider who wants to offer it. The September 14 FDA hearing on psychedelic treatment settings exists precisely because “approved by the FDA” and “available at your local clinic” are two different regulatory questions, and the second one is still unanswered for every psychedelic in this pipeline, ibogaine included.

Ground zero for this fight was Harvard, not Texas

If the politics here feel disorienting — a Republican administration championing a drug most Americans associate with 1960s counterculture — it’s worth naming the history it’s inverting. Psilocybin, LSD, MDMA, and ibogaine were all placed in Schedule I by the Controlled Substances Act of 1970, in the direct aftermath of Timothy Leary’s Harvard Psilocybin Project being shut down and a broader political backlash against psychedelic research that had nothing to do with the drugs’ actual therapeutic data — some of which, from the 1950s and early ’60s, showed real promise for alcoholism and end-of-life anxiety. That research didn’t resume in any serious institutional way for over three decades. It took Johns Hopkins reopening a psilocybin research program in 2000, and the nonprofit MAPS spending more than $150 million and thirty years building the clinical case for MDMA-assisted therapy for PTSD, to drag psychedelics back into a lab with FDA oversight at all. We have watched a government decide, once, that the politics of a drug mattered more than the medicine — and it cost the field three decades. The current acceleration is the opposite failure mode: it risks deciding the politics matter more than the medicine again, just in the other direction.

What actually changes for a family calling about it this week

None of this changes what a treatment-seeking family should do this week if a loved one is asking about ibogaine: it remains illegal to prescribe in the United States outside the new DemeRx trial, which is enrolling a small Phase I cohort, not accepting general patients. The clinics abroad that VETS and others refer veterans to operate outside FDA and, in most cases, outside comparable regulatory oversight — the cardiac risk that keeps ibogaine in Schedule I here doesn’t disappear because the clinic is in Mexico or Costa Rica instead. The honest read for psychedelics and empathogens broadly this year is that the pipeline is real, the political will behind it is real, and the timeline to an actual prescription is still measured in years — not because Washington is dragging its feet anymore, but because a drug that can stop a heart deserves the years it’s finally starting to get.